Management of non-invasive tumours, benign tumours and breast cancer during the COVID-19 pandemic: recommendations based on a Latin American survey.
breast cancer
coronavirus
survey method
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
05
2020
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
20
11
2020
Statut:
epublish
Résumé
The COVID-19 pandemic has changed health systems across the world, both in general hospitals and in oncology institutes or centres.For cancer specialists, particularly breast cancer (BC), the COVID-19 pandemic represents a combination of challenges since the hospital resources and staff have become more limited; this has obliged oncology specialists to seek a consensus and establish which patients with BC require more urgent attention and which patients can wait until there is a better control of this pandemic. The health system in Latin America has some special characteristics; in some of the countries, there are shortages which limit access to several specialities (surgery, clinical oncology and radiotherapy) in some regions. After a systematic review of the most recent literature regarding the management of BC during the COVID-19 pandemic, the main objective is to understand the position of the different Latin American Societies of Mastology in terms of available alternatives for the treatment of BC. After carrying out a comprehensive and exhaustive search of the most recent guides on the management of BC during the COVID-19 pandemic, the board members of the Latin American Federation of Mastology invited, via email, different specialists, all experts in BC care, to complete an anonymous survey online.The survey was distributed between 30 and 10 May 2020. The survey included 27 questions on four topics: demographic information, consultations, imaging and treatment of BC.The questionnaire was sent and then distributed to various health specialists including breast surgeons, clinical oncologists, radiation oncologists and radiologists via the Presidents of the different Latin American Societies of Mastology in 18 countries. The results are summarised as tallies based on the number of responses to each question. A total of 499 responses were received. The majority of the respondents were males (275 (55.11%)); 290 participants were over 45 years (58.11%).The questionnaire presented those surveyed with three possible answers (agree, disagree and neither agree nor disagree). The results reflect that there was consensus in the majority of situations presented. Only seven questions revealed disagreement among those responding. The results are presented as recommendations. The management of patients with BC presents unique challenges during the current world health situation produced by COVID-19 pandemic. Breast care specialists (surgical oncologists, breast care clinicians, clinical oncologists, radiation oncologists and radiologists) from 18 countries in Central and South America submitted through their responses and recommendations for the treatment of BC during the COVID-19 pandemic.
Identifiants
pubmed: 33209106
doi: 10.3332/ecancer.2020.1115
pii: can-14-1115
pmc: PMC7652542
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1115Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
The authors have not declared any conflicts of interest.
Références
Gland Surg. 2017 Feb;6(1):1-3
pubmed: 28210546
Ann Surg. 1998 Apr;227(4):496-501
pubmed: 9563536
Ann Surg Oncol. 2020 Feb;27(2):386-396
pubmed: 31562602
J Am Coll Radiol. 2018 Mar;15(3 Pt A):408-414
pubmed: 29371086
Breast Cancer Res Treat. 2020 Jun;181(3):487-497
pubmed: 32333293
J Clin Anesth. 1994 Jan-Feb;6(1):47-51
pubmed: 8142099
N Engl J Med. 2020 Apr 30;382(18):1679-1681
pubmed: 32160451
JAMA Oncol. 2016 Mar;2(3):330-9
pubmed: 26659430
Breast J. 2020 Jul;26(7):1485-1487
pubmed: 32383321
Breast. 2018 Apr;38:39-44
pubmed: 29223797
JAMA Surg. 2018 Jun 1;153(6):559-568
pubmed: 29387884
N Engl J Med. 2012 Jul 5;367(1):79-82
pubmed: 22762325
Mayo Clin Proc. 2013 Jan;88(1):68-73
pubmed: 23274020
J Clin Oncol. 2012 Dec 20;30(36):4485-92
pubmed: 23169513
Ann Surg Oncol. 2016 May;23(5):1515-21
pubmed: 26678405
Eur J Cancer. 2015 Aug;51(12):1497-510
pubmed: 26025767
Ann Surg Oncol. 2018 Jul;25(7):1936-1942
pubmed: 29748884
Breast Cancer Res Treat. 2004 Nov;88(2):187-96
pubmed: 15564801
Lancet Oncol. 2020 May;21(5):629-630
pubmed: 32247319
J Clin Oncol. 2004 Dec 1;22(23):4691-9
pubmed: 15570071
Ann Surg Oncol. 2020 Jul;27(7):2111-2113
pubmed: 32378088
J Clin Oncol. 2003 Feb 1;21(3):555-63
pubmed: 12560449
Lancet Oncol. 2013 Apr;14(5):391-436
pubmed: 23628188